Literature DB >> 21445949

Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura.

Arwa Z Al-Riyami1, James Lee, Mary Connolly, Evan Shereck.   

Abstract

We present a pediatric patient treated with high dose intravenous immunoglobulin (IVIG) for acute immune thrombocytopenic purpura (ITP), who developed cerebral sinus thrombosis in the absence of any identifiable hypercoagulable state. This report describes the successful management of this rare complication in this challenging setting. This report shows IVIG induced cerebral sinus thrombosis in ITP.
Copyright © 2011 Wiley-Liss, Inc., A Wiley Company.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21445949     DOI： 10.1002/pbc.22968

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  9 in total

1.  Management of myocardial infarction in immune thrombocytopenic purpura with anti-phospholipid antibodies.

Authors:  Rie Tabata; Chiharu Tabata; Yoshio Kita
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

Review 2.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

3.  Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.

Authors:  Wendy J Langeberg; W Marieke Schoonen; Melissa Eisen; Laurence Gamelin; Scott Stryker
Journal:  Int J Hematol       Date:  2016-03-24       Impact factor: 2.490

Review 4.  Thrombocytopenia and thrombosis: a double-edged sword.

Authors:  Myat Tun Lin Nyo; Asgar Ali Kalla
Journal:  Clin Rheumatol       Date:  2013-11-07       Impact factor: 2.980

Review 5.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 6.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

7.  Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.

Authors:  Takeo Hasegawa; Yuki Ozaki; Takuya Inoue; Yuzuru Watanabe; Mitsuro Fukuhara; Takumi Yamaura; Satoshi Muto; Naoyuki Okabe; Mitsunori Higuchi; Yutaka Shio; Hiroyuki Suzuki
Journal:  J Med Case Rep       Date:  2019-10-24

8.  Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report.

Authors:  Si-Ying Song; Zhong-Ao Wang; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

9.  iTRAQ-based quantitative proteomics analysis of immune thrombocytopenia patients before and after Qishunbaolier treatment.

Authors:  Yanbo Wang; Shuanglian Wang; Cuiqin Gong; Haihua Bai
Journal:  Rapid Commun Mass Spectrom       Date:  2021-02-15       Impact factor: 2.586
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.